Low-dose liver radiation to boost immunotherapy
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) or melanoma.
- Your cancer has spread to your liver (seen on imaging).
- Your doctor plans to treat you with a standard immunotherapy called a PD-1 or PD-L1 checkpoint inhibitor.
- If you have NSCLC, you do not have certain gene changes like EGFR, ALK, ROS1, or RET.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This trial tests whether adding radiation to the liver can make immunotherapy and chemotherapy work better for people with lung cancer that has spread to the liver. It's for patients who have already tried standard treatments, including immunotherapy, and need new options.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.